Tiziana Announces Positive Data on Intranasal Anti-CD3 Monoclonal Antibody in Intracerebral Hemorrhage
Tiziana Life Sciences (TLSA) has announced plans to advance foralumab, a fully human anti-CD3 monoclonal antibody, into human trials targeting hemorrhagic stroke. Recent pre-clinical data indicates significant behavioral improvement in motor and cognitive functions one month after treatment in a model of intracerebral hemorrhage. The mechanism involves modulation of neuroinflammation through the induction of FoxP3+ Tregs, which may lead to enhanced recovery in stroke patients. Tiziana is actively pursuing clinical development, with Phase 2 trials of intranasal foralumab anticipated to initiate in Q3 2023.
- Significant behavioral outcomes improvement noted in pre-clinical models of hemorrhagic stroke.
- Foralumab represents a novel treatment avenue for stroke patients, potentially addressing a critical unmet need.
- Encouraging Phase 2 trial plans for intranasal foralumab in patients with non-active SPMS.
- None.
- Tiziana planning to advance foralumab, the only fully human anti-CD3 monoclonal antibody, into human testing for hemorrhagic stroke
- Data shows behavioral outcomes improvement at one month in model of intracerebral hemorrhage (hemorrhagic stroke)
- Modulation of neuroinflammation by inducing FoxP3+ Tregs appears to have beneficial effect in intracerebral hemorrhage
NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced pre-clinical data on the effects of intranasal anti-CD3 monoclonal antibody in a model of intracerebral hemorrhage (hemorrhagic stroke) demonstrating a behavioral outcome improvement at one month.
“Less than
About Foralumab
Activated T cells play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets. This effect has been demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects. Intranasal foralumab Phase 2 trials are expected to start in the third quarter of 2023 in patients with non-active SPMS. Immunomodulation by nasal anti-CD3 mAb represents a novel avenue for treatment of inflammatory human diseases.1
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
Investors:
Irina Koffler
LifeSci Advisors, LLC
646.970.4681
ikoffler@lifesciadvisors.com
_______________________
1 https://www.pnas.org/doi/10.1073/pnas.2220272120
FAQ
What recent advancements has Tiziana Life Sciences made regarding foralumab?
What improvements were shown in the pre-clinical data for foralumab?
When will Tiziana initiate Phase 2 trials for intranasal foralumab?